Syndax Pharmaceuticals, Inc.
SNDX
$10.48
-$0.53-4.81%
| Weiss Ratings | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.77 | |||
| Price History | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -20.33% | |||
| 30-Day Total Return | -31.10% | |||
| 60-Day Total Return | -19.91% | |||
| 90-Day Total Return | -37.24% | |||
| Year to Date Total Return | -25.43% | |||
| 1-Year Total Return | -53.97% | |||
| 2-Year Total Return | -45.74% | |||
| 3-Year Total Return | -40.03% | |||
| 5-Year Total Return | 14.88% | |||
| 52-Week High % Change | -56.08% | |||
| 52-Week Low % Change | 8.58% | |||
| Price | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $25.07 | |||
| 52-Week Low Price | $10.14 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Jul 16, 2024 | |||
| Valuation | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 947.13M | |||
| Enterprise Value | 709.95M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.73 | |||
| Earnings Per Share Growth | 25.63% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 39.89 | |||
| Price/Book (Q) | 3.27 | |||
| Enterprise Value/Revenue (TTM) | 29.98 | |||
| Price | $10.50 | |||
| Enterprise Value/EBITDA (TTM) | -2.09 | |||
| Enterprise Value/EBIT | -2.09 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 85.79M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 419 1400 | |||
| Address | 730 Third Avenue New York, NY 10017 | |||
| Website | www.syndax.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -1,434.42% | |||
| Profit Margin | -1,346.10% | |||
| Management Effectiveness | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.74% | |||
| Return on Equity | -- | |||
| Income Statement | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 23.68M | |||
| Total Revenue (TTM) | 23.68M | |||
| Revenue Per Share | $0.28 | |||
| Gross Profit (TTM) | -166.44M | |||
| EBITDA (TTM) | -339.66M | |||
| EBIT (TTM) | -339.67M | |||
| Net Income (TTM) | -318.76M | |||
| Net Income Avl. to Common (TTM) | -318.76M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -29.94% | |||
| EPS Diluted (TTM) | -3.73 | |||
| EPS Diluted Growth (Q YOY) | -9.32% | |||
| Balance Sheet | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 582.91M | |||
| Cash Per Share (Q) | $6.79 | |||
| Total Current Assets (Q) | 603.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 288.12M | |||
| Current Ratio (Q) | 5.824 | |||
| Book Value Per Share (Q) | $3.36 | |||
| Total Assets (Q) | 724.82M | |||
| Total Current Liabilities (Q) | 103.55M | |||
| Total Debt (Q) | 345.74M | |||
| Total Liabilities (Q) | 436.69M | |||
| Total Common Equity (Q) | 288.12M | |||
| Cash Flow | SNDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -219.78M | |||
| Cash from Financing (TTM) | 353.37M | |||
| Net Change in Cash (TTM) | -141.31M | |||
| Levered Free Cash Flow (TTM) | -155.26M | |||
| Cash from Operations (TTM) | -274.90M | |||
